Donanemab for lewy body disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 15 May 2026: Trial registered, NCT07589595
  2. 20 May 2026: Trial started, NCT07589595

The trials

NCT07589595: A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

State
Under way
Phase
Phase 2
People
350 planned
Started
20 May 2026
Primary completion
Aug 2028
Arms
Donanemab (LY3002813)
Results
None posted
  1. 15 May 2026: Trial registered
  2. 20 May 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.